T cell immune memory after covid-19 and vaccination

L Wang, A Nicols, L Turtle, A Richter… - BMJ …, 2023 - pmc.ncbi.nlm.nih.gov
The T cell memory response is a crucial component of adaptive immunity responsible for
limiting or preventing viral reinfection. T cell memory after infection with the SARS-CoV-2 …

Respiratory syncytial virus infections in adults: a narrative review

JG Wildenbeest, DM Lowe, JF Standing… - The Lancet Respiratory …, 2024 - thelancet.com
Respiratory syncytial virus (RSV), an RNA virus spread by droplet infection that affects all
ages, is increasingly recognised as an important pathogen in adults, especially among older …

T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19

R Zonozi, LC Walters, A Shulkin, V Naranbhai… - Science translational …, 2023 - science.org
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe
disease and mortality from coronavirus disease 2019 (COVID-19), but the immune …

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

JF Standing, L Buggiotti, JA Guerra-Assuncao… - Nature …, 2024 - nature.com
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …

SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis

Z Raglow, D Surie, JD Chappell, Y Zhu… - The Lancet …, 2024 - thelancet.com
Summary Background Prolonged SARS-CoV-2 infections in people who are
immunocompromised might predict or source the emergence of highly mutated variants. The …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau, IFN Hung… - Nature …, 2023 - nature.com
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Impact of prior COVID-19 immunization and/or prior infection on immune responses and clinical outcomes

A Livieratos, C Gogos, K Akinosoglou - Viruses, 2024 - mdpi.com
Cellular and humoral immunity exhibit dynamic adaptation to the mutating SARS-CoV-2
virus. It is noteworthy that immune responses differ significantly, influenced by whether a …

A Genome-Wide Analysis of Promoter-Mediated Phenotypic Noise in Escherichia coli

OK Silander, N Nikolic, A Zaslaver, A Bren, I Kikoin… - PLoS …, 2012 - journals.plos.org
Gene expression is subject to random perturbations that lead to fluctuations in the rate of
protein production. As a consequence, for any given protein, genetically identical organisms …

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO) …

CS Goodyear, A Patel, E Barnes… - The Lancet …, 2024 - thelancet.com
Background The humoral and T-cell responses to booster COVID-19 vaccine types in
multidisease immunocompromised individuals who do not generate adequate antibody …

[HTML][HTML] Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases

E Anderson, M Powell, E Yang, A Kar, TM Leung… - JCI …, 2024 - pmc.ncbi.nlm.nih.gov
Patients with autoimmune diseases are at higher risk for severe infection due to their
underlying disease and immunosuppressive treatments. In this real-world observational …